middle.news
AdAlta Moves Manufacturing of CAR-T Therapy to Australia After Rare Tumour Clearance
8:56am on Wednesday 29th of April, 2026 AEST
•
Biotechnology
Read Story
AdAlta Moves Manufacturing of CAR-T Therapy to Australia After Rare Tumour Clearance
8:56am on Wednesday 29th of April, 2026 AEST
Key Points
Australian manufacturing transfer signed with Cell Therapies Pty Ltd
BZDS1901 shows 20% complete tumour clearance in advanced mesothelioma
Patient alive 22 months post-treatment with no tumour recurrence
Manufacturing site to support global trials and commercial scale-up
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
AdAlta (ASX:1AD)
OPEN ARTICLE